Use of a Mouse Model to Elucidate the Phenotypic Effects of the Von Willebrand Factor Cleavage Mutants, Y1605A/M1606A and R1597W

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2012 Mar 1

PMID 22372972

Citations 12

Authors

C M Pruss

M Golder

A Bryant

C Hegadorn

S Haberichter

D Lillicrap

Affiliations

Soon will be listed here.

Abstract

Background: von Willebrand Factor (VWF) is tightly regulated by the metalloproteinase ADAMTS13, which cleaves VWF to reduce VWF multimer size and binding affinity for collagen and platelets.

Objective: This study examines two VWF mutations, R1597W (enhanced cleavage) and Y1605A-M1606A (decreased cleavage), to determine their impact on VWF, in addition to ADAMTS13-mediated cleavage.

Methods: In vitro mouse ADAMTS13 digestions were performed on recombinant proteins. VWF knockout mice received hydrodynamic injections of mouse Vwf cDNA, following which VWF antigen, multimer profile and VWF propeptide levels were determined. A ferric chloride injury model of thrombosis was also evaluated.

Results: In vitro ADAMTS13 digestion of full-length mouse VWF required > 97-fold higher ADAMTS13 levels for Y1605A/M1606A, and 68% lower ADAMTS13 levels for R1597W compared with wild type. In vivo, R1597W had reduced VWF:Ag and both mutations exhibited increased VWF propeptide/VWF:Ag ratios. R1597W multimers show a lower molecular weight profile compared with wild type and Y1605A/M1606A mice. When co-injected with Adamts13 cDNA, Y1605A/M1606A multimers were larger compared with wild type, and R1597W showed only a single multimer band and decreased clearance via VWFpp/VWF:Ag ratio. R1597W was associated with reduced thrombus formation but normal platelet accumulation in a ferric chloride injury model while Y1605A/M1606A had a loss of occlusive thrombi but increased platelet accumulation compared with wild type.

Conclusions: This study demonstrates that mutations that alter ADAMTS13 cleavage also can affect VWF clearance, VWF antigen level, multimer structure and thrombotic potential in the VWF knockout hydrodynamic injection model.

Citing Articles

Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances.

Suda T, Yokoo T, Kanefuji T, Kamimura K, Zhang G, Liu D Pharmaceutics. 2023; 15(4).

PMID: 37111597 PMC: 10141091. DOI: 10.3390/pharmaceutics15041111.

The mechanistic and structural role of von Willebrand factor in endotoxemia-enhanced deep vein thrombosis in mice.

Choi S, Dwyer C, Rapkin L, Cormier M, Hindmarch C, Nesbitt K J Thromb Haemost. 2023; 21(3):586-598.

PMID: 36696220 PMC: 11552101. DOI: 10.1016/j.jtha.2022.11.022.

Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Zakas P, Coyle C, Brehm A, Bayer M, Solecka-Witulska B, Radford C Blood Adv. 2021; 5(3):812-822.

PMID: 33560395 PMC: 7876868. DOI: 10.1182/bloodadvances.2020002971.

Multimerin 1 supports platelet function in vivo and binds to specific GPAGPOGPX motifs in fibrillar collagens that enhance platelet adhesion.

Leatherdale A, Parker D, Tasneem S, Wang Y, Bihan D, Bonna A J Thromb Haemost. 2020; 19(2):547-561.

PMID: 33179420 PMC: 7898486. DOI: 10.1111/jth.15171.

Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombus.

Shida Y, Swystun L, Brown C, Mewburn J, Nesbitt K, Danisment O Res Pract Thromb Haemost. 2019; 3(2):254-260.

PMID: 31011709 PMC: 6462754. DOI: 10.1002/rth2.12196.

References

Lyons S, Bruck M, BOWIE E, Ginsburg D . Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. J Biol Chem. 1992; 267(7):4424-30. View

Banno F, Kaminaka K, Soejima K, Kokame K, Miyata T . Identification of strain-specific variants of mouse Adamts13 gene encoding von Willebrand factor-cleaving protease. J Biol Chem. 2004; 279(29):30896-903. DOI: 10.1074/jbc.M314184200. View

de Groot R, Lane D, Crawley J . The ADAMTS13 metalloprotease domain: roles of subsites in enzyme activity and specificity. Blood. 2010; 116(16):3064-72. PMC: 2974611. DOI: 10.1182/blood-2009-12-258780. View

Denis C, Methia N, Frenette P, Rayburn H, Hynes R, Wagner D . A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998; 95(16):9524-9. PMC: 21371. DOI: 10.1073/pnas.95.16.9524. View

Plaimauer B, Zimmermann K, Volkel D, Antoine G, Kerschbaumer R, Jenab P . Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002; 100(10):3626-32. DOI: 10.1182/blood-2002-05-1397. View

Zhang P, Pan W, Rux A, Sachais B, Zheng X . The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007; 110(6):1887-94. PMC: 1976376. DOI: 10.1182/blood-2007-04-083329. View

Hassenpflug W, Budde U, Obser T, Angerhaus D, Drewke E, Schneppenheim S . Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis. Blood. 2005; 107(6):2339-45. DOI: 10.1182/blood-2005-04-1758. View

Baronciani L, Federici A, Cozzi G, Canciani M, Mannucci P . von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M. J Thromb Haemost. 2006; 4(9):2088-90. DOI: 10.1111/j.1538-7836.2006.02069.x. View

Sadler J . Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67:395-424. DOI: 10.1146/annurev.biochem.67.1.395. View

10.

Bruno K, Volkel D, Plaimauer B, Antoine G, Pable S, Motto D . Cloning, expression and functional characterization of the full-length murine ADAMTS13. J Thromb Haemost. 2005; 3(5):1064-73. DOI: 10.1111/j.1538-7836.2005.01246.x. View

11.

Banno F, Chauhan A, Kokame K, Yang J, Miyata S, Wagner D . The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood. 2008; 113(21):5323-9. PMC: 2686194. DOI: 10.1182/blood-2008-07-169359. View

12.

Moake J . von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol. 2004; 41(1):4-14. DOI: 10.1053/j.seminhematol.2003.10.003. View

13.

Raife T, Cao W, Atkinson B, Bedell B, Montgomery R, Lentz S . Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood. 2009; 114(8):1666-74. PMC: 2731642. DOI: 10.1182/blood-2009-01-195461. View

14.

Varadi K, Rottensteiner H, Vejda S, Weber A, Muchitsch E, Turecek P . Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost. 2009; 7(7):1134-42. DOI: 10.1111/j.1538-7836.2009.03453.x. View

15.

Zhang X, Halvorsen K, Zhang C, Wong W, Springer T . Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science. 2009; 324(5932):1330-4. PMC: 2753189. DOI: 10.1126/science.1170905. View

16.

Chitta M, Duhe R, Kermode J . Cloning of the cDNA for murine von Willebrand factor and identification of orthologous genes reveals the extent of conservation among diverse species. Platelets. 2007; 18(3):182-98. DOI: 10.1080/09537100600938816. View

17.

Auton M, Cruz M, Moake J . Conformational stability and domain unfolding of the Von Willebrand factor A domains. J Mol Biol. 2006; 366(3):986-1000. DOI: 10.1016/j.jmb.2006.10.067. View

18.

Zanardelli S, Crawley J, Chion C, Lam J, Preston R, Lane D . ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 2005; 281(3):1555-63. DOI: 10.1074/jbc.M508316200. View

19.

Marx I, Christophe O, Lenting P, Rupin A, Vallez M, Verbeuren T . Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood. 2008; 112(3):603-9. DOI: 10.1182/blood-2008-02-142943. View

20.

Lenting P, Westein E, Terraube V, Ribba A, Huizinga E, Meyer D . An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem. 2003; 279(13):12102-9. DOI: 10.1074/jbc.M310436200. View